Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis
Giovanni Sotgiu,Rosella Centis,Lia D'Ambrosio,Jan-William C. Alffenaar,Holly Anger,Jose A. Caminero,Paolo Castiglia,Saverio De Lorenzo,Giovanni Ferrara,Giovanni Ferrara,Won-Jung Koh,Giesela F. Schecter,Tae Sun Shim,Rupak Singla,Alena Skrahina,Antonio Spanevello,Zarir F Udwadia,Miguel Villar,Elisabetta Zampogna,Jean-Pierre Zellweger,Alimuddin Zumla,Giovanni Battista Migliori +21 more
TLDR
The study results suggest an excellent efficacy but also the necessity of caution in the prescription of linezolid, and the proportion of adverse events was significantly higher when the lineZolid daily dosage exceeded 600 mg.Abstract:
Linezolid is used off-label to treat multidrug-resistant tuberculosis (MDR-TB) in absence of systematic evidence. We performed a systematic review and meta-analysis on efficacy, safety and tolerability of linezolid-containing regimes based on individual data analysis. 12 studies (11 countries from three continents) reporting complete information on safety, tolerability, efficacy of linezolid-containing regimes in treating MDR-TB cases were identified based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Meta-analysis was performed using the individual data of 121 patients with a definite treatment outcome (cure, completion, death or failure). Most MDR-TB cases achieved sputum smear (86 (92.5%) out of 93) and culture (100 (93.5%) out of 107) conversion after treatment with individualised regimens containing linezolid (median (inter-quartile range) times for smear and culture conversions were 43.5 (21-90) and 61 (29-119) days, respectively) and 99 (81.8%) out of 121 patients were successfully treated. No significant differences were detected in the subgroup efficacy analysis (daily linezolid dosage ≤ 600 mg versus >600 mg). Adverse events were observed in 63 (58.9%) out of 107 patients, of which 54 (68.4%) out of 79 were major adverse events that included anaemia (38.1%), peripheral neuropathy (47.1%), gastro-intestinal disorders (16.7%), optic neuritis (13.2%) and thrombocytopenia (11.8%). The proportion of adverse events was significantly higher when the linezolid daily dosage exceeded 600 mg. The study results suggest an excellent efficacy but also the necessity of caution in the prescription of linezolid.read more
Citations
More filters
Journal ArticleDOI
Advances in the development of new tuberculosis drugs and treatment regimens
TL;DR: Current concepts and recent advances in TB drug discovery and development are covered, including an update of ongoing TB treatment trials, newer clinical trial designs, TB biomarkers and adjunct host-directed therapies.
Journal ArticleDOI
The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis
Keertan Dheda,Tawanda Gumbo,Gary Maartens,Kelly E. Dooley,Ruth McNerney,Megan Murray,Jennifer Furin,Edward A. Nardell,Leslie London,Erica Lessem,Grant Theron,Paul D. van Helden,Stefan Niemann,Matthias Merker,David W. Dowdy,Annelies Van Rie,Annelies Van Rie,Gilman Kit Hang Siu,Jotam G. Pasipanodya,Camilla Rodrigues,Taane G. Clark,F. A. Sirgel,Aliasgar Esmail,Hsien-Ho Lin,Sachin R Atre,H. Simon Schaaf,Kwok Chiu Chang,Christoph Lange,Payam Nahid,Zarir F Udwadia,C. Robert Horsburgh,Gavin J. Churchyard,Gavin J. Churchyard,Dick Menzies,Anneke C. Hesseling,Eric L. Nuermberger,Helen McIlleron,Kevin P. Fennelly,Eric Goemaere,Ernesto Jaramillo,Marcus Low,Carolina Morán Jara,Nesri Padayatchi,Robin M. Warren +43 more
TL;DR: Several lines of evidence suggest that alternative mechanisms-including pharmacokinetic variability, induction of efflux pumps that transport the drug out of cells, and suboptimal drug penetration into tuberculosis lesions-are likely crucial to the pathogenesis of drug-resistant tuberculosis.
Journal ArticleDOI
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial
Andreas H. Diacon,Rodney Dawson,Florian von Groote-Bidlingmaier,Gregory Symons,Amour Venter,Peter R. Donald,Christo van Niekerk,Daniel Everitt,Helen Winter,Piet J. Becker,Mendel Carl M,Melvin Spigelman +11 more
TL;DR: PA-824-moxifloxacin-pyrazinamide is potentially suitable for treating drug-sensitive and multidrug-resistant tuberculosis and can contribute to reducing the time needed to develop new antituberculosis regimens.
Journal ArticleDOI
Therapeutic drug monitoring in the treatment of tuberculosis: an update
TL;DR: Therapeutic drug monitoring (TDM) remains a standard clinical technique for using plasma drug concentrations to determine dose, and under ‘real–life’ circumstances is the best available tool for sorting out these multi-drug interactions, and for providing the patient safe and adequate doses.
Journal ArticleDOI
New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects
Alimuddin Zumla,Alimuddin Zumla,Stephen H. Gillespie,Michael Hoelscher,Patrick P J Philips,Stewart T. Cole,Ibrahim Abubakar,Timothy D. McHugh,Marco Schito,Markus Maeurer,Andrew J. Nunn +10 more
TL;DR: The need to engage the community in design, implementation, and uptake of research is emphasised, to increase international cooperation between drug developers and health-care providers adopting new regimens.
References
More filters
Journal ArticleDOI
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
TL;DR: Moher et al. as mentioned in this paper introduce PRISMA, an update of the QUOROM guidelines for reporting systematic reviews and meta-analyses, which is used in this paper.
Journal Article
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
TL;DR: The QUOROM Statement (QUality Of Reporting Of Meta-analyses) as mentioned in this paper was developed to address the suboptimal reporting of systematic reviews and meta-analysis of randomized controlled trials.
Journal ArticleDOI
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
TL;DR: A structured summary is provided including, as applicable, background, objectives, data sources, study eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, conclusions and implications of key findings.
Journal ArticleDOI
Meta-DiSc: a software for meta-analysis of test accuracy data
TL;DR: Meta-DiSc is a comprehensive and dedicated test accuracy meta-analysis software that has already been used and cited in several meta-analyses published in high-ranking journals and is publicly available.
Journal ArticleDOI
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
Dennis Falzon,Ernesto Jaramillo,Holger J. Schünemann,Matthew Arentz,Melissa Bauer,Jaime Bayona,Léopold Blanc,Jose A. Caminero,Charles L. Daley,Chris Duncombe,Christopher Fitzpatrick,Agnes Gebhard,Haileyesus Getahun,Myriam Henkens,Timothy H. Holtz,J. Keravec,S. Keshavjee,Aamir J. Khan,R. Kulier,Vaira Leimane,Christian Lienhardt,Chunling Lu,Mar'iandyshev Ao,Giovanni Battista Migliori,Fuad Mirzayev,Carole D. Mitnick,Paul Nunn,G. Nwagboniwe,Olivia Oxlade,Domingo Palmero,Patricia B Pavlinac,M. I. D. Quelapio,Mario C. Raviglione,Michael Rich,S. Royce,Sabine Rüsch-Gerdes,A. Salakaia,R. Sarin,Delphine Sculier,Francis Varaine,Marco Vitoria,Judd L. Walson,Fraser Wares,Karin Weyer,Richard A. White,Matteo Zignol +45 more
TL;DR: The guidelines promote the early use of antiretroviral agents for TB patients with HIV on second-line drug regimens and systems that primarily employ ambulatory models of care are recommended over others based mainly on hospitalisation.
Related Papers (5)
Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis
Myungsun Lee,Jongmin Lee,Matthew W. Carroll,Hongjo Choi,Seonyeong Min,Taeksun Song,Laura E. Via,Lisa C. Goldfeder,Eunhwa Kang,Boyoung Jin,Hyeeun Park,Hyun-Kyung Kwak,Hyun-Chul Kim,Han Seung Jeon,Ina Jeong,Joon Sung Joh,Ray Y. Chen,Kenneth N. Olivier,Pamela A. Shaw,Dean Follmann,Sun Dae Song,Jong Koo Lee,Duk-Hyoung Lee,Cheon Tae Kim,Véronique Dartois,Seung-kyu Park,Sang Nae Cho,Clifton E. Barry +27 more
Delamanid for Multidrug-Resistant Pulmonary Tuberculosis
Maria Tarcela Gler,Vija Skripconoka,Epifanio Sanchez-Garavito,Heping Xiao,Jose L. Cabrera-Rivero,Dante E. Vargas-Vasquez,Mengqiu Gao,Mohamed A. Awad,Seung Kyu Park,Tae Sun Shim,Gee Young Suh,Manfred Danilovits,Hideo Ogata,Anu Kurve,Joon Chang,Katsuhiro Suzuki,Thelma E. Tupasi,Won-Jung Koh,Barbara J. Seaworth,Lawrence Geiter,Charles D. Wells +20 more
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
Dennis Falzon,Ernesto Jaramillo,Holger J. Schünemann,Matthew Arentz,Melissa Bauer,Jaime Bayona,Léopold Blanc,Jose A. Caminero,Charles L. Daley,Chris Duncombe,Christopher Fitzpatrick,Agnes Gebhard,Haileyesus Getahun,Myriam Henkens,Timothy H. Holtz,J. Keravec,S. Keshavjee,Aamir J. Khan,R. Kulier,Vaira Leimane,Christian Lienhardt,Chunling Lu,Mar'iandyshev Ao,Giovanni Battista Migliori,Fuad Mirzayev,Carole D. Mitnick,Paul Nunn,G. Nwagboniwe,Olivia Oxlade,Domingo Palmero,Patricia B Pavlinac,M. I. D. Quelapio,Mario C. Raviglione,Michael Rich,S. Royce,Sabine Rüsch-Gerdes,A. Salakaia,R. Sarin,Delphine Sculier,Francis Varaine,Marco Vitoria,Judd L. Walson,Fraser Wares,Karin Weyer,Richard A. White,Matteo Zignol +45 more
Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline
The diarylquinoline TMC207 for multidrug-resistant tuberculosis
Andreas H. Diacon,Alexander S. Pym,Martin P. Grobusch,R. F. Patientia,Roxana Rustomjee,Liesl Page-Shipp,Christoffel Pistorius,Rene Krause,Mampedi Bogoshi,Gavin J. Churchyard,Amour Venter,Jenny Allen,Juan Carlos Palomino,Tine De Marez,Rolf van Heeswijk,Nacer Lounis,Paul Meyvisch,Johan Verbeeck,Wim Parys,Karel de Beule,Koen Andries,David F Mc Neeley +21 more